Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAIDEN Trial: Y90 Radioembolization + Tremelimumab + Durvalumab in Cholangiocarcinoma
NCT06058663Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab and durvalumab in cholangiocarcinoma (CCA) (2 cohorts), sponsored by Mayo Clinic. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jun 2024; status: recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06058663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058663.